Drug intelligence / Profile preview

AmEno

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Oral

Overview

AmEno is a moonlighting protein, specifically enolase AmEno15, identified from the *Anaplasma marginale* strain MEX-15-099-01. It is being investigated for its potential as an immunogen in the design of vaccines against bovine Anaplasmosis. Synthetic peptides derived from AmEno have demonstrated antigenicity in ELISA assays, indicating its potential for stimulating an immune response. AmEno plays a significant role in the adhesion and invasion processes of *Anaplasma marginale* to host tissues, including erythrocytes and tick gut cells.

Beyond the preview

Go deeper on AmEno.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmEno.

Explore the full profile